BioCryst Pharmaceuticals BCRX Payments to Acquire Productive Assets
Payments to Acquire Productive Assets at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireProductiveAssets.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's payments to acquire productive assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's payments to acquire productive assets?
- BioCryst Pharmaceuticals (BCRX) reported payments to acquire productive assets of $403K in Q1 2026.
- How has BioCryst Pharmaceuticals's payments to acquire productive assets changed year-over-year?
- BioCryst Pharmaceuticals's payments to acquire productive assets increased by 181.8% year-over-year, from $143K to $403K.
- What is the long-term trend for BioCryst Pharmaceuticals's payments to acquire productive assets?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's payments to acquire productive assets has grown at a 0.9% compound annual growth rate (CAGR), from $2.39M to $2.47M.
- What does payments to acquire productive assets mean?
- Represents cash outflows for the acquisition of property, plant, equipment, or other long-term tangible assets used in operations. This metric reflects the company's investment in its physical infrastructure and capacity to support research, development, or manufacturing activities.